Clinical and Practice Considerations in the Management of Iron Deficiency Anemia with IV Infusion
By: Jorge Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Drug Brown and White Bagging - What is It and Where Does it Lead Us?
By: Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach
By: Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Navigating Payor Barriers to Access of Oncology Pharmaceuticals: Real-World Case Approach
By: Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Will Biosimilars Reduce Financial Toxicity of Cancer Therapy
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Drug Brown and White Bagging: What is It and Where Does it Lead Us?
By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE
Drug Brown and White Bagging: What is It and Where Does it Lead Us?
By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE
Payor Benefits Design Changing Oncology Care Delivery
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Clinical and Practice Considerations in the Management of Iron Deficiency Anemia
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
White Bagging & The Movement for Policy Development
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Development of Pharmacy-Led Ambulatory Infusion Services (Part 1)
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
White-Bagging Journey in Florida; Strategies to Protect Practice and Patients
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE & Kenneth Komorny, PharmD, BCPS
White-Bagging Journey in Florida; Strategies to Protect Practice and Patients
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE & Kenneth Komorny, PharmD, BCPS
Diabetes Management in the Face of Healthcare Disparities
By: Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM
Obesity Management with Incretin Therapies: Considerations for Patients with and without Type 2 Diabetes
By: Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM
Diabetes Management in the Face of Healthcare Disparities
By: Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM
Obesity Management with Incretin Therapies: Considerations for Patients with and without Type 2 Diabetes
By: Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM
Oncology Pharmacy Training; A Discussion with Kelley Carlstrom
By: Kelley D. Carlstrom, PharmD, BCOP
